Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CYMP antisense RNA 1 (CYMP-AS1)
- Target
- CYMP-AS1
- Molecular classification
- Long non-coding RNA (lncRNA), Natural antisense transcript
01
Overview
CYMP antisense RNA 1 (CYMP-AS1) is a 2,579-nucleotide long non-coding RNA, mapped to human chromosome 1p13.3. CYMP-AS1 is upregulated in ovarian cancer tissues and localized predominantly in the cytoplasm but also present in the nucleus. It exerts pro-oncogenic functions by interacting with hnRNPM, facilitating its nuclear shuttling, and reducing the stability of AXIN2 mRNA. This regulation promotes activation of the Wnt/β-catenin signaling pathway, advancing cell proliferation, migration, invasion, and EMT. CYMP-AS1 is thus both a mechanistic driver and a novel biomarker for ovarian cancer progression, with proposed targeting strategies including antisense-based modalities.
- Other names
- CYMP-AS1
02
Mechanism of action
Not applicable; direct-acting drugs are not reported. Mechanistically, targeting CYMP-AS1 (e.g., with antisense oligonucleotides or siRNA) would inhibit its interaction with heterogeneous nuclear ribonucleoprotein M (hnRNPM), restore AXIN2 mRNA stability, and downregulate the Wnt/β-catenin pathway.
03
Biological functions
Regulation of mRNA stability (specifically AXIN2 mRNA)Promotion of cell proliferationPromotion of cell migrationPromotion of cell invasionInduction of epithelial-mesenchymal transition (EMT)Regulation of Wnt/β-catenin signaling pathway
04
Disease associations
Cancer, specifically ovarian cancer (progression, metastasis, prognosis)
05
Safety considerations
No notable safety concerns or therapeutic challenges addressed in the literature. As with other lncRNA-directed therapeutics, off-target effects and efficient delivery are general concerns for future applications.
06
Biomarkers
CYMP-AS1 expression is a biomarker for ovarian cancer progression and poor prognosis, correlating with metastasis and tumor stage
Beyond the preview
Go deeper on CYMP antisense RNA 1 (CYMP-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CYMP antisense RNA 1 (CYMP-AS1).